Safety of Treatment of Latent Tuberculosis Infection in Compensated Cirrhotic Patients During Transplant Candidacy Period
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Treatment of latent tuberculosis infection with isoniazid (INH) or rifampin (RIF) is controversial in liver transplant candidates due to potential hepatotoxicity. In this study, treatment of latent tuberculosis during transplant candidacy period is explored, and relevant literature is reviewed. METHODS: Liver transplant candidates with latent tuberculosis infection by positive tuberculin skin test (>5 mm) were prospectively enrolled and treated with 9 months of INH or 4 months of RIF, and were monitored monthly for their liver enzyme profiles, adverse effects, compliance, and completion rate. RESULTS: Four of nine patients with INH had asymptomatic, mild elevations of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) versus none of five patients in the RIF group. Two cases of elevations were attributed to INH. Two other cases were attributed to alcoholism or active chronic hepatitis B virus infection. Only one patient in the INH group experienced symptoms possibly attributed to INH hepatotoxicity. Compliance was 100% per patient reporting. Completion rates were 79% for INH and 100% for RIF. No fulminant hepatic failure or death was observed. CONCLUSION: Treatment of latent tuberculosis in liver transplant patients during their candidacy with INH or RIF appears to be a safe, viable option, if carefully monitored for adverse effects and liver enzymes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis
Prince, M. I., Burt, A. D., & Jones, D. E. J. (2002) · Gut · doi:10.1136/gut.50.3.436 · Cited by 202
Cited by
Martin, P., DiMartini, A., Feng, S., Brown, R., & Fallon, M. (2014) · Hepatology · doi:10.1002/hep.26972 · Cited by 1,045
“There had been concerns previously about hepatotoxicity with anti-TB regimens but more recent experience with isoniazid has been reassuring in LT candidates with cirrhosis.(63,64) Syphilis, if detected, needs to be treated pre-LT.”
BackgroundThe risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement
Bumbacea, D., Arend, S. M., Eyuboglu, F., Fishman, J. A., Goletti, D., Ison, M. G., Jones, C. E., Kampmann, B., Kotton, C. N., Lange, C., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00000712 · Cited by 264
Mycobacterial infections in solid organ transplant recipients
Meije, Y., Piersimoni, C., Torre-Cisneros, J., Dilektasli, A. G., & Aguado, J. M. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12641 · Cited by 124
Hepatotoxicity from antituberculous therapy in the elderly: a systematic review
Hosford, J. D., von Fricken, M. E., Lauzardo, M., Chang, M., Dai, Y., Lyon, J. A., Shuster, J., & Fennelly, K. P. (2015) · Tuberculosis · doi:10.1016/j.tube.2014.10.006 · Cited by 63
Metadata
- Authors
- Jahng, A. W., Tran, T., Bui, L., & Joyner, J. L.
- Venue
- Transplantation
- Published
- 2007-06-27
- Volume
- 83
- Issue
- 12
- Pages
- 1557-1562
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2043008180
- Cited by
- 67
- References
- 1
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of Treatment of Latent Tuberculosis Infection in Compensated Cirrhotic Patients During Transplant Candidacy Period. https://app.cochat.ai/papers/10.1097/01.tp.0000266578.45634.4f
- The paper
- Jahng, A. W., Tran, T., Bui, L., & Joyner, J. L. (2007). Safety of Treatment of Latent Tuberculosis Infection in Compensated Cirrhotic Patients During Transplant Candidacy Period. Transplantation. https://doi.org/10.1097/01.tp.0000266578.45634.4f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.